Novel inhalation therapy moves to animal trials in US $3 Billion fast-track COVID-19 treatments program under Dr Anthony Fauci
It’s not easy being a small player in a market where big pharma looms large. But a small MELBOURNE - MISSOULA group with big ambitions in the antimicrobial resistance space may be about to crack it.
The Biden Administration is investing more than $3 billion in a whole of government program with a focus on accelerated development of next generation COVID-19 treatments. The announcement was made on 17 June 2021 by Dr. Anthony Fauci, chief medical adviser to the President and US National Institute for Allergy and Infectious Diseases (NIAID) Director. Dr Fauci said
“Through multidisciplinary collaborations among leading scientists in academia and industry,
this investment from the American Rescue Plan to create the Antiviral Program for
Pandemics will help inspire medical innovation…”
One of Wintermute Biomedical’s novel water based fatty acid compounds, known as GS-12, has already demonstrated highly encouraging in-vitro data as a potential inhaled COVID-19 therapy under the NIAID program and it as now be accepted to progress into animal studies.
“GS-12 is a remarkably simple drug which uses our platform technology to release the antimicrobial agency of fatty acids. In this case, animal trials will test the positive in vitro results of GS-12 against the Sars-Cov-2 virus” said Wintermute Biomedical CEO, Brett Carter.
“GS-12 takes advantage of the protein spike structure of coronaviruses like Sars-Cov-2. Our hypothesis is that it neutralises the virus by binding to the protein spike.” said Chief Scientific Officer and Founder of Wintermute Biomedical, Dr Thomas Rau.
“The components GS-12 are already on the FDA’s Generally Regarded As Safe list so the regulatory pathway could be relatively quick should the animal trials be successful. We also know that GS-12 is broad spectrum and effective against fungi. This could be a breakthrough for COVID-19 lung infections complicated by mixed fungal infections and for other types of
pneumonia” said Dr. Rau.
About Wintermute Biomedical, Inc.
Wintermute Biomedical, Inc. is a small biotechnology company based in both Missoula, Montana and Melbourne, Australia. It has a range of fatty acid-amino acid combinations that have varying antimicrobial agency. Besides GS-12, the company has developed Doxall™ sanitisers and TGA-approved disinfectant. The group also has an FDA-approved topical antifungal that it is pursuing as a shingles therapy. Wintermute is working with several universities and research agencies to investigate other potential drug candidates.
For further information please contact:
Chief Executive Officer
+61 416 454 588
Link to NIAID announcement